Literature DB >> 3338013

Brain tumors in the very young child. Postoperative chemotherapy in combined-modality treatment.

M E Horowitz1, R K Mulhern, L E Kun, E Kovnar, R A Sanford, J Simmons, F A Hayes, J J Jenkins.   

Abstract

Twelve consecutively diagnosed children with brain tumors, ages 7 to 27 months, were treated by a combined-modality approach featuring aggressive surgical resection followed by chemotherapy and delayed irradiation. Patients received multiple clinical neurologic examinations and psychological evaluations, as well as diagnostic imaging studies, to monitor the efficacy of chemotherapy and toxic effects of therapy. Six of the eight children with residual tumor evident postoperatively on computed tomography scans had objective responses to chemotherapy. The efficacy of chemotherapy was further demonstrated by the lack of disease progression for 7 months or longer in eight children, seven of whom remain free of tumor 19 to 57 months (median, 28 months) from the date of diagnosis. The neurologic status of ten patients improved during treatment. Developmental progress was normal in two, low average in three, and frankly deficient in four of ten children formally evaluated. These results indicate that postoperative chemotherapy, added to a regimen of surgical resection and delayed irradiation, prolong survival with only minimal short term neurotoxicity in the majority of very young children with malignant brain tumors.

Entities:  

Mesh:

Year:  1988        PMID: 3338013     DOI: 10.1002/1097-0142(19880201)61:3<428::aid-cncr2820610304>3.0.co;2-a

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  17 in total

Review 1.  Toward a cure for infants with brain tumours: the challenge for the 1990's.

Authors:  P M Zeltzer
Journal:  Br J Cancer Suppl       Date:  1992-08

2.  Will high dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma?

Authors:  S Dupuis-Girod; O Hartmann; E Benhamou; F Doz; F Mechinaud; E Bouffet; C Coze; C Kalifa
Journal:  J Neurooncol       Date:  1996-01       Impact factor: 4.130

3.  MOPP chemotherapy without irradiation as primary postsurgical therapy for brain tumors in infants and young children.

Authors:  J L Ater; J van Eys; S Y Woo; B Moore; D R Copeland; J Bruner
Journal:  J Neurooncol       Date:  1997-05       Impact factor: 4.130

4.  Preirradiation chemotherapy.

Authors:  J L Finlay
Journal:  Childs Nerv Syst       Date:  1994-07       Impact factor: 1.475

Review 5.  High dose chemotherapy with autologous stem cell rescue for patients with medulloblastoma.

Authors:  I J Dunkel; J L Finlay
Journal:  J Neurooncol       Date:  1996-07       Impact factor: 4.130

6.  Supratentorial tumours in infants.

Authors:  M K Tewari; B S Sharma; R K Mahajan; V K Khosla; S N Mathuriya; A Pathak; V K Kak
Journal:  Childs Nerv Syst       Date:  1994-04       Impact factor: 1.475

7.  Postoperative chemotherapy without radiation in young children with malignant non-astrocytic brain tumours. A report from the Australia and New Zealand Childhood Cancer Study Group (ANZCCSG).

Authors:  L White; H Johnston; R Jones; H Mameghan; V Nayanar; W McWhirter; S Kellie; K Waters; I Toogood
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 8.  Treatment of infants with malignant gliomas: the Pediatric Oncology Group experience.

Authors:  P K Duffner; J P Krischer; P C Burger; M E Cohen; J W Backstrom; M E Horowitz; R A Sanford; H S Friedman; L E Kun
Journal:  J Neurooncol       Date:  1996 May-Jun       Impact factor: 4.130

Review 9.  Chemotherapy as prophylaxis and treatment of meningosis in children less than 3 years of age with medulloblastoma.

Authors:  S Schmandt; J Kühl
Journal:  J Neurooncol       Date:  1998 Jun-Jul       Impact factor: 4.130

10.  Successful treatment for a metastatic supratentorial malignant rhabdoid tumor.

Authors:  E Bouffet; D Frappaz; D Dolbeau; H Sobol; A Jouvet; C Carrie; C Pondarre; M Brunat-Mentigny; T Philip; C Mottolese
Journal:  J Neurooncol       Date:  1993-07       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.